
|Articles|November 15, 2002
Once-daily glaucoma therapy better tolerated than b.i.d.
Houston-In patients with primary open-angle glaucoma (POAG) or ocular hypertension (OH), once-daily treatment with fixed-combination latanoprost/timolol (Xalacom, Pharmacia, Peapack, NJ) is well tolerated and lowers IOP more effectively than twice-daily dorzolamide/timolol (Cosopt, Merck), according to a recent multicenter U.S. study.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
FDA approves carbachol–brimonidine eye drop for presbyopia following phase 3 BRIO trials
2
Study finds artificial tear viscosity and shear-thinning behavior vary by formulation
3
Eye exams could enable earlier detection of systemic disease
4
MacTel Decoded: Rethinking Conventional Approaches with Novel Neuroprotective Strategies
5



























